An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
Novo Nordisk’s weight-loss drug Wegovy just got approval in China to be used for a liver disease called NASH (nonalcoholic steatohepatitis). In plain terms, a medication that many people know because it helps with weight loss can now be prescribed in China for a specific kind of fatty liver that causes inflammation and scarring. Wegovy’s active ingredient is semaglutide. Semaglutide is a man-made version of a natural hormone your gut releases after you eat. That hormone tells your brain you’re full and slows how quickly food leaves your stomach. Doctors first used semaglutide-type drugs to treat diabetes, and higher doses were later approved to help people lose weight because they reduce appetite and calorie intake. The approval in China is about treating NASH, which is fatty liver disease not caused by alcohol. NASH can progress to serious liver damage. The evidence that led to this approval comes from clinical trials where people with NASH were given semaglutide and researchers looked at liver inflammation, fat, and scarring. Results have shown that semaglutide can reduce liver fat and inflammation and can improve certain markers seen on biopsies and scans. That said, effects on advanced scarring (called fibrosis) have been less clear or smaller in many studies, and the size and duration of trials vary. If you want exact numbers and how big the benefits were, you’d need to look at the specific trials that regulators reviewed. Why this matters: millions of people worldwide have fatty liver disease, often linked to obesity, diabetes, or metabolic syndrome. There haven’t been many approved medicines for NASH, so having a well-known drug gain approval expands treatment options. For patients in China, this means another tool their doctors can use to try to reduce liver inflammation and possibly slow progression of the disease. It also matters economically and medically because it signals growing global acceptance of semaglutide for conditions beyond weight loss. Important caveats: semaglutide can cause side effects, commonly nausea, vomiting, diarrhea, and constipation, especially when treatment starts or doses increase. Rare but serious risks include pancreatitis (pancreas inflammation) and changes in the gallbladder. The drug affects appetite and digestion, so it’s not suitable for everyone; people with certain medical histories or pregnant people shouldn’t use it. Approval for NASH doesn’t mean it reverses severe cirrhosis or fixes all liver damage. Also, regulatory approval means authorities judged benefits outweigh risks for the approved use in China, but long-term effects and how it performs in broader patient groups still need monitoring. Bottom line: A drug many know for weight loss, semaglutide (Wegovy), has been approved in China to treat a form of fatty liver disease, offering a new treatment option while still carrying known side effects and some remaining uncertainties about long-term impact.
Source: 一财全球Yicai Global